What further hematology workup is indicated for this 52-year-old female with seizure disorder, hypertension, hyperlipidemia, depression/anxiety, advanced FIGO grade 1 endometrioid adenocarcinoma with bilateral ovarian and omental involvement, dMMR/MSI-H, TMB 12, who after carboplatin/paclitaxel/pembrolizumab therapy developed febrile neutropenia, pancytopenia, and a high HScore suggestive of hemophagocytic syndrome?

Further Hematology Workup

Proceed immediately with bone marrow biopsy to evaluate for hemophagocytosis, assess marrow cellularity and architecture, and exclude infiltrative disease or infection, while simultaneously obtaining soluble IL-2 receptor, CXCL9, IL-18, and NK cell function testing to confirm or refute hemophagocytic lymphohistiocytosis (HLH).

Rationale for Bone Marrow Evaluation

Your patient's HScore of 231 corresponds to a 98–99% probability of reactive hemophagocytic syndrome 1. The bone marrow biopsy planned for [DATE] is the single most critical diagnostic step. This procedure must evaluate:

• Hemophagocytosis: Direct visualization of macrophages engulfing erythrocytes, leukocytes, platelets, or their precursors confirms HLH pathophysiology and would increase the HScore to 266 (>99% probability)
• Marrow cellularity and trilineage assessment: The profoundly suppressed reticulocyte production (absolute count 0.007 million/µL, immature fraction 2.1%) indicates marrow failure rather than peripheral destruction
• Infiltrative disease: Rule out marrow involvement by endometrial adenocarcinoma, although uncommon in endometrioid histology
• Infectious organisms: Special stains (GMS, PAS, acid-fast) and cultures for fungi, mycobacteria, and atypical organisms, particularly given the pelvic washing cytology showing fungal organisms
• Dysplasia or secondary myeloid neoplasm: Exclude therapy-related myelodysplastic syndrome, though timing after single chemotherapy cycle makes this unlikely

Pending Biomarker Panel

The soluble IL-2 receptor, CXCL9, and IL-18 levels already sent are essential for HLH diagnosis and should be expedited. These cytokine markers:

• Soluble IL-2 receptor >2400 U/mL strongly supports HLH
• CXCL9 and IL-18 elevations correlate with disease activity and may help distinguish primary HLH from secondary causes
• Results will guide immunosuppression intensity and duration

Hemolysis Evaluation

The hemolysis workup you've initiated is appropriate given the microcytic anemia (MCV 79.5 fL) with elevated RDW (17.7%) and suppressed reticulocyte response. Specifically assess:

• Direct antiglobulin test (DAT): Rule out immune-mediated hemolysis, which can occur with pembrolizumab 1
• Indirect bilirubin, haptoglobin, LDH fractionation: Current LDH 887 U/L may reflect hemolysis, tissue destruction, or both
• Peripheral smear review: Look for schistocytes (microangiopathic hemolysis), spherocytes (immune hemolysis), or atypical cells

The microcytosis suggests either iron deficiency from chronic bleeding or anemia of inflammation. Check iron studies (ferritin already markedly elevated at 3,207 ng/mL, but obtain transferrin saturation and soluble transferrin receptor to distinguish true iron deficiency from functional iron restriction in inflammation).

Coagulation Assessment

Your patient's declining fibrinogen (294→237 mg/dL), elevated D-dimer (1.414 µg/mL FEU), and thrombocytopenia (51 K/µL) raise concern for consumptive coagulopathy. Obtain:

• PT/INR and aPTT: Assess for DIC or acquired factor deficiencies
• Fibrin degradation products: Complement D-dimer elevation
• Thromboelastography (TEG) if available: Provides real-time assessment of clot formation and fibrinolysis

Infectious Disease Coordination

Despite extensive negative workup, the gram-positive cocci in pairs from [DATE] blood culture requires definitive identification and repeat cultures. While awaiting results:

• Continue empiric ceftriaxone as initiated
• Do not restart systemic antifungals unless Fungitell (1,3-β-D-glucan) or Aspergillus galactomannan return positive, or clinical deterioration occurs. The pelvic washing fungi preceded hysterectomy and lack radiographic correlate 2
• Repeat blood cultures if fever persists after 48–72 hours of appropriate antibiotics
• Consider echocardiography to exclude endocarditis given persistent bacteremia and port presence

Transfusion Thresholds and Growth Factor Use

Your current transfusion strategy is appropriate 3:

• PRBC transfusion: Hemoglobin <7 g/dL or symptomatic (current 8.2 g/dL)
• Platelet transfusion: <10 K/µL, <20 K/µL with fever, or <50 K/µL for bone marrow biopsy
• No additional G-CSF: ANC 1.39 K/µL is adequate; further G-CSF may exacerbate inflammatory syndrome 3

Distinguishing HLH from Checkpoint Inhibitor Toxicity

The clinical picture overlaps significantly between pembrolizumab-associated cytokine release syndrome (CRS), immune-related adverse events (irAEs), and secondary HLH. Key discriminators:

• HLH features present: Hyperferritinemia (3,207 ng/mL), hypertriglyceridemia (417 mg/dL), hypofibrinogenemia (237 mg/dL), pancytopenia, hepatitis, and high fever 1
• CRS typically occurs: Within hours to days of infusion, not 2–3 weeks later
• Pembrolizumab-associated HLH: Well-documented phenomenon, particularly in combination with chemotherapy 4

The methylprednisolone 1 mg/kg IV initiated is appropriate first-line therapy for both HLH and severe irAEs 1. If no improvement within 48–72 hours or clinical deterioration, escalate to:

• High-dose methylprednisolone 10–30 mg/kg/day for refractory HLH
• Consider etoposide-based HLH therapy (etoposide 150 mg/m² twice weekly) if bone marrow confirms hemophagocytosis and steroid response inadequate
• IVIG 1 g/kg may be added for immune-mediated cytopenias

Monitoring During Immunosuppression

Given infection risk with high-dose steroids:

• Daily CBC with differential (already being done)
• Twice-weekly comprehensive metabolic panel to monitor transaminitis and electrolytes
• Serial ferritin, triglycerides, fibrinogen every 2–3 days to assess HLH activity
• Pneumocystis jirovecii prophylaxis: Initiate trimethoprim-sulfamethoxazole or alternative if steroids continue beyond 2 weeks
• Fungal prophylaxis: Consider fluconazole given oral thrush and prolonged immunosuppression

Lumbar Puncture Timing

Defer LP until platelets >50 K/µL post-transfusion. Indications to proceed despite risks:

• Worsening encephalopathy despite metabolic correction
• New focal neurological deficits
• MRI findings suggesting CNS inflammation or infection
• Persistent fever without identified source after bone marrow results

Pembrolizumab-associated encephalitis remains on differential but is rare 1.

Common Pitfalls to Avoid

1. Attributing all findings to infection: The negative infectious workup, marked hyperferritinemia, and HScore strongly favor hyperinflammatory syndrome over occult infection alone
2. Delaying bone marrow biopsy: This is the definitive diagnostic test and should not be postponed
3. Continuing G-CSF: May worsen inflammatory state; bandemia likely G-CSF-related 3
4. Under-treating confirmed HLH: If hemophagocytosis confirmed, steroids alone may be insufficient—etoposide-based therapy has established efficacy
5. Premature systemic antifungals: No current indication given negative imaging and biomarkers pending

Algorithmic Approach Summary

1. Immediate: Bone marrow biopsy with hemophagocytosis assessment, cultures, flow cytometry, cytogenetics
2. Within 24 hours: Expedite soluble IL-2 receptor, CXCL9, IL-18 results; complete hemolysis panel; coagulation studies
3. Ongoing: Continue methylprednisolone 1 mg/kg IV; monitor inflammatory markers every 2–3 days
4. If bone marrow shows hemophagocytosis: Escalate to HLH-directed therapy (high-dose steroids ± etoposide)
5. If no hemophagocytosis but clinical deterioration: Consider pembrolizumab-associated severe irAE and escalate immunosuppression
6. After platelet transfusion to >50 K/µL: Reassess need for LP based on neurological status

The distinction between pembrolizumab-associated toxicity and secondary HLH may be academic—both require aggressive immunosuppression, and the bone marrow findings will guide therapy intensity 1, 4.